HPS-162 - Risk of ocular adverse events with Trastuzumab: A case report

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-162
• By: HUANG, Tzu Yu (Min-Sheng General Hospital, China Taiwan)
• Co-author(s): Pharmacist Tzu Yu Huang
  
• Abstract:

  Background
  Trastuzumab is a monoclonal antibody targeting the HER-2/neu antigen. It inhibits cancer cells that overexpress HER-2/neu. Approximately 25–30% of breast cancer patients exhibit HER-2 overexpression. Studies indicate that these patients generally have a poorer prognosis compared to those without HER-2 overexpression. Common adverse..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login